Cargando…

Conversion of abiraterone to D4A drives antitumor activity in prostate cancer

Prostate cancer resistance to castration occurs because tumors acquire the metabolic capability of converting precursor steroids to 5α-dihydrotestosterone (DHT), promoting signaling by the androgen receptor (AR) and the development of castration-resistant prostate cancer (CRPC)(1–3). Essential for r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhenfei, Bishop, Andrew, Alyamani, Mohammad, Garcia, Jorge A., Dreicer, Robert, Bunch, Dustin, Liu, Jiayan, Upadhyay, Sunil K., Auchus, Richard J., Sharifi, Nima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506215/ https://www.ncbi.nlm.nih.gov/pubmed/26030522 http://dx.doi.org/10.1038/nature14406

Ejemplares similares

Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy
por: Li, Zhenfei, et al.
Publicado: (2016)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
por: Li, Jianneng, et al.
Publicado: (2017)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients
por: Liu, Ying, et al.
Publicado: (2022)

Targeted non AR mediated smart delivery of abiraterone to the prostate cancer
por: Baker, Abu, et al.
Publicado: (2022)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site
por: Petrunak, Elyse M., et al.
Publicado: (2023)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
por: Tani, Masaru, et al.
Publicado: (2023)

Abiraterone Acetate
Publicado: (2012)

Response of prostate cancer to addition of dutasteride after progression on abiraterone
por: Lian, Jian-Po, et al.
Publicado: (2020)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer
por: McSweeney, Sean, et al.
Publicado: (2022)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets
por: Patel, Amol, et al.
Publicado: (2020)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
por: Shah, Yash B., et al.
Publicado: (2022)

Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2014)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

Abiraterone: moving up in line?
por: Strijbos, Michiel
Publicado: (2018)

Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition
por: Ornstein, Moshe C., et al.
Publicado: (2016)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
por: James, Aloysius, et al.
Publicado: (2018)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
por: Castellan, Pietro, et al.
Publicado: (2018)

Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
por: Kulkarni, A.A., et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
por: Lott, Felipe
Publicado: (2020)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
por: Zhang, Ying, et al.
Publicado: (2022)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eopuu9qekgf27kplbdunavueo1